For pediatric patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL), residential fine particulate matter (PMâ‚‚.â‚… ...
A new review explains how targeted immunotherapies are stripping predictive power from traditional risk markers in adult ...
ZYNLONTA is a CD19-directed antibody-drug conjugate approved by the U.S. FDA and conditionally approved by the European Commission for certain patients with relapsed or refractory DLBCL after two or ...
After Sanofi paid $600 million in cash to acquire Dren Bio’s bispecific last year, the biotech has secured a hefty financing ...
Genmab stock surged on strong Phase 3 cancer data, but valuation and patent risks remain. Click here to read this recent ...
ADC Therapeutics SA announced that its Japanese licensing partner, Tanabe Pharma Corporation, filed a marketing authorization application with Japan's Ministry of Health, Labor and Welfare on October ...
About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody ...
Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer diagnosis ...
Sequencing and re-expressing B cell receptors from lymphoma tissue of rheumatoid arthritis patients reveals polyreactive and ...
B cell subsets contribute to long-term tumor control and improved overall patient survival in multiple tumor types.
Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...
When treatment is urgent, are there clues to foresee the outcome?When you are told of a relapse and must start the next treatment as soon as possible, the first thing many people want to know is, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results